TriangleNCT01353222 · REGISTRY CONDITION SEARCH
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE2
- Status at capture
- TERMINATED
- Registry last update
- 2017-05-25
This study was conducted to examine survival, disease-free survival, safety, and the magnitude of the immune response induced following administration of DN24-02 in subjects with HER2+ urothelial carcinoma.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Histopathologic evidence of urothelial carcinoma, based on local pathology report. * High risk urothelial carcinoma, in subjects with or without prior neoadjuvant chemotherapy, defined as positive lymph node status (N+), or pathological stage ≥ pathological tumor (pT2) in patients who either have negative lymph node status (N0) or have no evaluable lymph nodes (Nx). * Radical surgical resection was performed ≤ 84 days (12 weeks) prior to registration. * No evidence of residual disease or metastasis following surgical resection which includes: absence of invasive cancer at the margins in the surgical specimens and confirmation by CT scan of chest, abdomen and pelvis obtained at least 28 days following surgical resection and ≤ 28 days prior to registration. * HER2/neu tissue expression ≥ 1+ by immunohistochemistry (IHC). Available biopsy specimens from the primary tumor and involved lymph nodes are be submitted to the central pathology laboratory prior to registration for confirmation of HER2/neu tissue expression. * Last neoadjuvant chemotherapy treatment administered at least 60 days prior to registration. * Left ventricular ejection fraction ≥ 50% on multigated acquisition (MUGA) scan or echocardiogram obtained at least 28 days following surgery and ≤ 28 days prior to registration. * Women of child-bearing potential have a negative serum pregnancy test result ≤ 28 days prior to registration and agree not to breastfeed during investigational treatment with DN24-02 and for 28 days following the final infusion of DN24-02. * All males and premenopausal females who have not been surgically sterilized have agreed to practice a method of birth control considered by the Investigator to be effective and medically acceptable for at least 14 days prior to registration, throughout treatment, and for 28 days following the final infusion of DN24-02. * Adequate hematologic, renal, and liver function. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. Exclusion Criteria: * A history of stage III or greater non-urothelial cancer. Exceptions include: Subject with basal or squamous cell skin cancers that has been adequately treated who are disease-free at the time of registration. Subjects who have been disease-free and off treatment for ≥ 10 years at the time of registration. * A history of stage I or II non-urothelial cancer. Exceptions include: Subjects who have been disease-free and off treatment for ≥ 3 years at the time of registration. Subjects with incidental prostate cancer diagnosed at the time of cystoprostatectomy. Subjects with basal or squamous cell skin cancer. * Partial cystectomy in the setting of bladder cancer primary tumor. * Partial nephrectomy in the setting of renal pelvis primary tumor. * Adjuvant systemic therapy for urothelial or prostatic carcinoma following surgical resection. * Adjuvant radiation therapy for urothelial or prostatic carcinoma following surgical resection. * Incidental prostate cancer with detectable post-operative (radical cystoprostatectomy) prostate specific antigen (PSA) levels ≤ 28 days prior to registration. * Any major surgery (e.g., surgery requiring general anesthesia) ≤ 28 days prior to registration. * Systemic treatment on any investigational clinical trial ≤ 28 days prior to registration. * Systemic glucocorticoid or immunosuppressive therapy use ≤ 28 days prior to registration. * Any infection requiring parenteral antibiotic therapy or causing fever (i.e., temperature \> 100.5°F or \> 38.1°C) ≤ 7 days prior to registration. * A history of allergic reactions attributed to compounds of similar chemical or biologic composition to DN24-02 or Granulocyte-macrophage colony-stimulating factor (GM-CSF). * Any medical intervention, has any other condition, or has any other circumstance which, in the opinion of the Investigator or the Dendreon Medical Monitor, could compromise adherence with study requirements or otherwise compromise the study's objectives.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Subjects received infusion of DN24-02, at 2-week intervals, for a total of 3 infusions.
- intervention Names
- Biological: DN24-02
- label
- DN24-02
- type
- EXPERIMENTAL
- description
- Subjects randomized to the control arm were treated per standard of care, which in this patient population is generally observation, as there is currently no evidence that treatment with non-cisplatin containing chemotherapy is beneficial in the adjuvant setting for this patient population.
- intervention Names
- Other: Standard of Care
- label
- Standard of Care
- type
- OTHER
- interventions
- arm Group Labels
- DN24-02
- description
- DN24-02 is an autologous cellular immunotherapy product designed to stimulate an immune response against HER2/neu. It consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), which are activated ex vivo with a recombinant fusion protein, BA7072.
- name
- DN24-02
- type
- BIOLOGICAL
- arm Group Labels
- Standard of Care
- description
- Observation only until documentation of disease recurrence.
- name
- Standard of Care
- type
- OTHER
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 142
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Overall survival is defined as the time from randomization to death due to any cause. \*This study was terminated early due to administrative reasons.
- measure
- Overall Survival
- time Frame
- Subjects will be followed from baseline through the remainder of their lives or until study completion (approximately 60 months)
Full study description
- brief Summary
- This study was conducted to examine survival, disease-free survival, safety, and the magnitude of the immune response induced following administration of DN24-02 in subjects with HER2+ urothelial carcinoma.
- detailed Description
- Multicenter, open-label, Phase 2 study. Subjects were randomized to either the investigational product, DN24-02, or to standard of care. Subjects randomized to the experimental arm received DN24-02 at 2-week intervals, for a total of 3 infusions. The study evaluated survival, disease-free survival, safety and the magnitude of the immune response between these 2 subject groups.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-8602a6db0df470b012b4
- requested nct id
- NCT01353222
- primary nct id
- NCT01353222
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- 308f79635904744c3081b7bece1bbf864685110f5917c0840a211e0e58d7fefc
- payload sha256
- 42d5769ecad53a2a262e541ee8dc5704c2f10e82d743abf10dbb088ef4720c2a
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-8602a6db0df470b012b4
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT01353222
- occurrences
- context exact
- NCT01353222
- end
- 11
- exact text
- NCT01353222
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Urethral Cancer
- query disease state id
- ds-urethral-cancer
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-urethral-cancer-000.json
- source file sha256
- 308f79635904744c3081b7bece1bbf864685110f5917c0840a211e0e58d7fefc
- source json pointer
- /studies/33/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- dafec1406a131bacb02124f839ff810a7ae1da2c8ffd74cce214fad62ee658d6
Preserved source evidence · Not medical advice